サマリー

欧州の遺伝子治療市場は、2023年から2030年にかけて18.3%のCAGRを記録すると予測されています。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年であり、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
欧州遺伝子治療市場、ベクタータイプ別（ウイルスベクター、非ウイルスベクター）、方法別（生体外、生体内）、用途別（腫瘍疾患、心血管疾患、感染症、希少疾患、神経疾患、その他の疾患）、エンドユーザー（がん研究所、病院、研究機関、その他）、国（ドイツ、フランス、英国、イタリア、ロシア、スペイン、オランダ、スイス、ベルギー、トルコ、欧州全域） 産業動向および2030年までの予測
遺伝子治療市場の成長に寄与する主な要因として、以下のものが挙げられます：

- 個別化医療の需要の高まり
- 遺伝性疾患の有病率の上昇
- 遺伝子治療の新たなアプローチ

市場のプレーヤー：

欧州の遺伝子治療市場の主要な市場関係者は以下の通りです：

- AGCバイオロジックス
- アムジェン社（Amgen, Inc.
- アンジェス社
- バイオジェン
- ブリストル・マイヤーズ スクイブ・カンパニー
- CHIESI Farmaceutici S.p.A.
- ヤンセン・ファーマシューティカルズ・インク
- カイトファーマ（ギリアド・サイエンシズ社の子会社）
- マリンクロッド
- ノバルティスAG
- オーチャード・セラピューティクス・ピーエルシー
- オックスフォード・バイオメディカ
- スパーク・セラピューティクス社（Spark Therapeutics, Inc.
- ユニキュアNV.

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE EUROPE GENE THERAPY MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 MARKET END USER COVERAGE GRID 32
2.8 PRODUCT LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 41
4.2 PORTER FIVE ANALYSIS 42
5 UPDATE ON GERMLINE GENE THERAPY 43
5.1 GERMLINE GENE THERAPY 43
6 EUROPE GENE THERAPY MARKET, MO 44
6.1 DRIVERS 46
6.1.1 NOVEL APPROACHES TO GENE THERAPY 46
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 46
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 47
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 48
6.2 RESTRAINTS 48
6.2.1 HIGH COST OF GENE THERAPY 48
6.2.2 ETHICAL AND SAFETY CONCERNS 49
6.2.3 COMPLEXITY OF GENE THERAPY 49
6.3 OPPORTUNITIES 50
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 50
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 50
6.4 CHALLENGES 51
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 51
6.4.2 LONG-TERM SAFETY AND EFFICACY 51
7 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE 52
7.1 OVERVIEW 53
7.2 VIRAL VECTOR 56
7.2.1 ADENOVIRUS 57
7.2.2 RETROVIRUS 57
7.2.3 LENTIVIRUS 57
7.2.4 ADENO-ASSOCIATED VIRUS 57
7.2.5 VACCINIA VIRUS 57
7.2.6 HERPES SIMPLEX VIRUS 57
7.2.7 OTHERS 57
7.3 NON-VIRAL VECTOR 57
7.3.1 LIPOFECTION 58
7.3.2 INJECTION OF NAKED DNA 58
8 EUROPE GENE THERAPY MARKET, BY METHOD 59
8.1 OVERVIEW 60
8.2 EX-VIVO 63
8.3 IN-VIVO 63
9 EUROPE GENE THERAPY MARKET, BY APPLICATION 65
9.1 OVERVIEW 66
9.2 ONCOLOGICAL DISORDERS 69
9.3 CARDIOVASCULAR DISEASES 69
9.4 INFECTIOUS DISEASES 70
9.5 RARE DISEASES 71
9.6 NUEROLOGICAL DISORDERS 72
9.7 OTHER DISEASES 73
10 EUROPE GENE THERAPY MARKET, BY END USER 74
10.1 OVERVIEW 75
10.2 CANCER INSTITUTES 78
10.3 HOSPITALS 78
10.4 RESEARCH INSTITUTES 79
10.5 OTHERS 80
11 EUROPE GENE THERAPY MARKET, BY REGION 81
11.1 EUROPE 82
11.1.1 GERMANY 88
11.1.2 FRANCE 90
11.1.3 U.K. 92
11.1.4 ITALY 94
11.1.5 SPAIN 96
11.1.6 RUSSIA 98
11.1.7 TURKEY 100
11.1.8 NETHERLANDS 102
11.1.9 BELGIUM 104
11.1.10 SWITZERLAND 106
11.1.11 REST OF EUROPE 108
12 EUROPE GENE THERAPY MARKET, COMPANY LANDSCAPE 109
12.1 COMPANY SHARE ANALYSIS: EUROPE 109
13 COMPANY PROFILES 110
13.1 BIOGEN 110
13.1.1 COMPANY SNAPSHOT 110
13.1.2 REVENUE ANALYSIS 110
13.1.3 COMPANY SHARE ANALYSIS 111
13.1.4 SWOT ANALYSIS 111
13.1.5 PRODUCT PORTFOLIO 112
13.1.6 RECENT DEVELOPMENT 112
13.2 KITE PHARMA 113
13.2.1 COMPANY SNAPSHOT 113
13.2.2 REVENUE ANALYSIS 113
13.2.3 COMPANY SHARE ANALYSIS 114
13.2.4 SWOT ANALYSIS 114
13.2.5 PRODUCT PORTFOLIO 115
13.2.6 RECENT DEVELOPMENT 115
13.3 NOVARTIS AG 116
13.3.1 COMPANY SNAPSHOT 116
13.3.2 REVENUE ANALYSIS 116
13.3.3 COMPANY SHARE ANALYSIS 117
13.3.4 SWOT ANALYSIS 117
13.3.5 PRODUCT PORTFOLIO 118
13.3.6 RECENT DEVELOPMENTS 118
13.4 BRISTOL-MYERS SQUIBB COMPANY. 119
13.4.1 COMPANY SNAPSHOT 119
13.4.2 REVENUE ANALYSIS 119
13.4.3 COMPANY SHARE ANALYSIS 120
13.4.4 SWOT ANALYSIS 120
13.4.5 PRODUCT PORTFOLIO 121
13.4.6 RECENT DEVELOPMENT 121
13.5 OXFORD BIOMEDICA 122
13.5.1 COMPANY SNAPSHOT 122
13.5.2 REVENUE ANALYSIS 122
13.5.3 COMPANY SHARE ANALYSIS 123
13.5.4 SWOT ANALYSIS 123
13.5.5 PRODUCT PORTFOLIO 124
13.5.6 RECENT DEVELOPMENTS 124
13.6 AGC BIOLOGICS 125
13.6.1 COMPANY SNAPSHOT 125
13.6.2 PRODUCT PORTFOLIO 125
13.6.3 RECENT DEVELOPMENT 125
13.7 ANGES, INC 126
13.7.1 COMPANY SNAPSHOT 126
13.7.2 REVENUE ANALYSIS 126
13.7.3 PRODUCT PORTFOLIO 127
13.7.4 RECENT DEVELOPMENT 127
13.8 AMGEN INC. 128
13.8.1 COMPANY SNAPSHOT 128
13.8.2 REVENUE ANALYSIS 128
13.8.3 PRODUCT PORTFOLIO 129
13.8.4 RECENT DEVELOPMENT 129
13.9 BLUEBIRD BIO, INC. 130
13.9.1 COMPANY SNAPSHOT 130
13.9.2 PRODUCT PORTFOLIO 130
13.9.3 RECENT DEVELOPMENT 130
13.10 CHIESI FARMACEUTICI S.P.A 131
13.10.1 COMPANY SNAPSHOT 131
13.10.2 REVENUE ANALYSIS 131
13.10.3 PRODUCT PORTFOLIO 132
13.10.4 RECENT DEVELOPMENT 132
13.11 DENDREON PHARMACEUTICALS LLC 133
13.11.1 COMPANY SNAPSHOT 133
13.11.2 PRODUCT PORTFOLIO 133
13.11.3 RECENT DEVELOPMENT 133
13.12 ENZYVANT THERAPEUTICS GMBH 134
13.12.1 COMPANY SNAPSHOT 134
13.12.2 RODUCT PORTFOLIO 134
13.12.3 RECENT DEVELOPMENT 134
13.13 FERRING B.V. 135
13.13.1 COMPANY SNAPSHOT 135
13.13.2 PRODUCT PORTFOLIO 135
13.13.3 RECENT DEVELOPMENT 135
13.14 JANSSEN PHARMACEUTICALS, INC. 136
13.14.1 COMPANY SNAPSHOT 136
13.14.2 PRODUCT PORTFOLIO 136
13.14.3 RECENT DEVELOPMENT 136
13.15 MALLINCKRODT. 137
13.15.1 COMPANY SNAPSHOT 137
13.15.2 REVENUE ANALYSIS 137
13.15.3 PRODUCT PORTFOLIO 138
13.15.4 RECENT DEVELOPMENT 138
13.16 ORCHARD THERAPEUTICS PLC. 139
13.16.1 COMPANY SNAPSHOT 139
13.16.2 REVENUE ANALYSIS 139
13.16.3 PRODUCT PORTFOLIO 140
13.16.4 RECENT DEVELOPMENT 140
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 141
13.17.1 COMPANY SNAPSHOT 141
13.17.2 PRODUCT PORTFOLIO 141
13.17.3 RECENT DEVELOPMENT 141
13.18 SIBONO 142
13.18.1 COMPANY SNAPSHOT 142
13.18.2 PRODUCT PORTFOLIO 142
13.18.3 RECENT DEVELOPMENT 142
13.19 SPARK THERAPEUTICS, INC. 143
13.19.1 COMPANY SNAPSHOT 143
13.19.2 PRODUCT PORTFOLIO 143
13.19.3 RECENT DEVELOPMENT 143
13.20 UNIQURE NV. 144
13.20.1 COMPANY SNAPSHOT 144
13.20.2 REVENUE ANALYSIS 144
13.20.3 PRODUCT PORTFOLIO 145
13.20.4 RECENT DEVELOPMENT 145
14 QUESTIONNAIRE 146
15 RELATED REPORTS 149

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 50
TABLE 2 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 51
TABLE 3 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 51
TABLE 4 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 53
TABLE 5 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 53
TABLE 6 EUROPE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 57
TABLE 7 EUROPE EX-VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 8 EUROPE IN –VIVO IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 9 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 63
TABLE 10 EUROPE ONCOLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 11 EUROPE CARDIOVASCULAR DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 12 EUROPE INFECTIOUS DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 13 EUROPE RARE DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 14 EUROPE NEUROLOGICAL DISORDERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 15 EUROPE OTHER DISEASES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 16 EUROPE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 72
TABLE 17 EUROPE CANCER INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 18 EUROPE HOSPITALS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 19 EUROPE RESEARCH INSTITUTES IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 20 EUROPE OTHERS IN GENE THERAPY MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 21 EUROPE GENE THERAPY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 81
TABLE 22 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 81
TABLE 23 EUROPE VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 81
TABLE 24 EUROPE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY TYPE, 2021-2030 (USD MILLION) 81
TABLE 25 EUROPE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 82
TABLE 26 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 82
TABLE 27 EUROPE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 82
TABLE 28 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 83
TABLE 29 GERMANY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 83
TABLE 30 GERMANY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 83
TABLE 31 GERMANY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 83
TABLE 32 GERMANY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 84
TABLE 33 GERMANY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 84
TABLE 34 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 85
TABLE 35 FRANCE VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 85
TABLE 36 FRANCE NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 85
TABLE 37 FRANCE GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 85
TABLE 38 FRANCE GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 86
TABLE 39 FRANCE GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 86
TABLE 40 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 87
TABLE 41 U.K. VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 87
TABLE 42 U.K. NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 87
TABLE 43 U.K. GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 87
TABLE 44 U.K. GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 88
TABLE 45 U.K. GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 88
TABLE 46 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 89
TABLE 47 ITALY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 89
TABLE 48 ITALY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 89
TABLE 49 ITALY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 89
TABLE 50 ITALY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 90
TABLE 51 ITALY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 90
TABLE 52 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 91
TABLE 53 SPAIN VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 91
TABLE 54 SPAIN NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 91
TABLE 55 SPAIN GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 91
TABLE 56 SPAIN GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 92
TABLE 57 SPAIN GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 92
TABLE 58 RUSSIA GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 93
TABLE 59 RUSSIA VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 93
TABLE 60 RUSSIA NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 93
TABLE 61 RUSSIA GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 93
TABLE 62 RUSSIA GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 94
TABLE 63 RUSSIA GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 94
TABLE 64 TURKEY GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 95
TABLE 65 TURKEY VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 95
TABLE 66 TURKEY NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 95
TABLE 67 TURKEY GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 95
TABLE 68 TURKEY GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 96
TABLE 69 TURKEY GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 96
TABLE 70 NETHERLANDS GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 71 NETHERLANDS VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 72 NETHERLANDS NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 97
TABLE 73 NETHERLANDS GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 97
TABLE 74 NETHERLANDS GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 98
TABLE 75 NETHERLANDS GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 98
TABLE 76 BELGIUM GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 99
TABLE 77 BELGIUM VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 99
TABLE 78 BELGIUM NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 99
TABLE 79 BELGIUM GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 99
TABLE 80 BELGIUM GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 100
TABLE 81 BELGIUM GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 100
TABLE 82 SWITZERLAND GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 101
TABLE 83 SWITZERLAND VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 101
TABLE 84 SWITZERLAND NON-VIRAL VECTOR IN GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 101
TABLE 85 SWITZERLAND GENE THERAPY MARKET, BY METHOD, 2021-2030 (USD MILLION) 101
TABLE 86 SWITZERLAND GENE THERAPY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 102
TABLE 87 SWITZERLAND GENE THERAPY MARKET, BY END USER, 2021-2030 (USD MILLION) 102
TABLE 88 REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2021-2030 (USD MILLION) 103